Stock Analysis

While shareholders of Hims & Hers Health (NYSE:HIMS) are in the black over 1 year, those who bought a week ago aren't so fortunate

NYSE:HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) shareholders might be concerned after seeing the share price drop 13% in the last week. But that doesn't detract from the splendid returns of the last year. Indeed, the share price is up an impressive 101% in that time. So it is important to view the recent reduction in price through that lense. Investors should be wondering whether the business itself has the fundamental value required to continue to drive gains.

While the stock has fallen 13% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

See our latest analysis for Hims & Hers Health

Hims & Hers Health wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Hims & Hers Health grew its revenue by 94% last year. That's well above most other pre-profit companies. Meanwhile, the market has paid attention, sending the share price soaring 101% in response. That sort of revenue growth is bound to attract attention, even if the company doesn't turn a profit. The strong share price rise indicates optimism, so there may be a better opportunity for buyers as the hype fades a bit.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

NYSE:HIMS Earnings and Revenue Growth March 12th 2023

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Hims & Hers Health stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

Pleasingly, Hims & Hers Health's total shareholder return last year was 101%. What is absolutely clear is that is far preferable to the dismal 2.9% average annual loss suffered over the last three years. It could well be that the business has turned around -- or else regained the confidence of investors. It's always interesting to track share price performance over the longer term. But to understand Hims & Hers Health better, we need to consider many other factors. Take risks, for example - Hims & Hers Health has 1 warning sign we think you should be aware of.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Valuation is complex, but we're here to simplify it.

Discover if Hims & Hers Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.